Page 32 - Merck Sharp News Today

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer ... | June 14, 2023

Drug companies like BMS, GSK and Amgen face revenue losses from patent expirations

LARGO, FL / ACCESSWIRE / June 13, 2023 / PharmaLink, Inc., an Industry-leading pharmaceutical reverse distributor, announced today a new contract relationship with biopharmaceutical manufacturer Merck

Guidelines recommending adjuvant treatment for stage III melanoma should be revisited, say researchers reporting a review of data that found no overall survival benefit.

Systemic treatment options have historically been limited to traditional chemotherapy agents.

The update builds on 2019 recommendations and incorporates safety concerns about JAK inhibitors, advises on differential drug efficacy across disease manifestations, and eliminates systemic steroids.

Datalys Recently announced Global Fibromyalgia Drugs Report 2023 Get Free Sample Report: Fibromyalgia Drugs Market Research Report 2023-2031An objecti

This randomized clinical trial compares the efficacy and safety of letermovir vs valganciclovir prophylaxis for cytomegalovirus (CMV) disease in CMV-seronegativ

One additional patient has developed a partial response (PR) and one patient has remained on stable disease for over 80 weeksThese long-lasting responses in hard-to-treat metastatic diseases, in patients

The antiviral letermovir has received a new FDA indication as prophylaxis for recipients of a cytomegalovirus (CMV)-seropositive kidney transplant.